Charles River Laboratories Intl. Inc vs Fortinet Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Fortinet Inc trades at $190.85 (market cap $138.75B). The key difference: Fortinet Inc is far larger — about 9.8× Charles River Laboratories Intl. Inc's market cap, and Fortinet Inc is more actively traded (2,956,908 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Fortinet Inc for 72 Days on average.
| CRL | FTNT | |
|---|---|---|
Market Cap | $14.23B | $138.75B |
Volume | 1,176,885 | 2,956,908 |
Sector | Health | Technology |
52-Week High | $310.77 | $191.27 |
52-Week Low | $149.93 | $75.23 |
Typical Hold Time | 33 Days | 72 Days |
Enterprise Value | $17.06B | $135.17B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
Fortinet (FTNT) trades at $189.28, down 1.04% on the day but near its 52-week high, supported by a bullish technical trend and strong moving averages. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.90 surpassing the $0.746 estimate. Revenue growth remains solid, climbing to $6.80 billion in 2025, while profitability metrics like a 28.17% net income margin and 117.44% ROE highlight operational efficiency. Recent news highlights AI-driven cybersecurity demand and raised 2026 guidance as key growth catalysts.
The outlook for FTNT is positive, driven by accelerating platform demand and AI security expansion, though elevated valuation ratios (P/E of 66.88) pose a risk if growth moderates. Analyst consensus leans bullish with a 42% buy rating, but the stock trades above the $158.64 average price target, suggesting near-term caution. Key risks include competitive pressures and execution challenges in sustaining high growth rates amid economic uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →